Unknown

Dataset Information

0

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern.

ABSTRACT: There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro, 3CLpro) that can be dosed orally and that is in clinical development. We here report that PF-332 exerts equipotent in vitro activity against the four SARS-CoV-2 variants of concerns (VoC) and that it can completely arrest replication of the alpha variant in primary human airway epithelial cells grown at the air-liquid interface. Treatment of Syrian Golden hamsters with PF-332 (250 mg/kg, twice daily) completely protected the animals against intranasal infection with the beta (B.1.351) and delta (B.1.617.2) SARS-CoV-2 variants. Moreover, treatment of SARS-CoV-2 (B.1.617.2) infected animals with PF-332 completely prevented transmission to untreated co-housed sentinels.

SUBMITTER: Abdelnabi R 

PROVIDER: S-EPMC8847371 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro, 3CLpro) that can be dosed orally and that is in clinical development. We here report that PF-332 exerts equipotent in vitro activity against the four SARS-CoV-2 variants of concerns (VoC) and that it can completely arrest replication of the alpha variant in primary human airway epithelial cells grown at the air-liquid interfac  ...[more]

Similar Datasets

Unknown Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332.
| S-EPMC8533666 | biostudies-literature
Unknown Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease.
| S-EPMC8491126 | biostudies-literature
Unknown The Expressional Pattern of Epididymal Protease Inhibitor (EPPIN) in the Male Syrian Hamsters.
| S-EPMC6182231 | biostudies-literature
Unknown Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332.
| S-EPMC8300928 | biostudies-literature
Unknown Structural basis of main proteases of HCoV-229E bound to inhibitor PF-07304814 and PF-07321332.
| S-EPMC10020134 | biostudies-literature
Unknown Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations.
| S-EPMC8430524 | biostudies-literature
Unknown Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M<sup>pro</sup> inhibitor in animal models.
| S-EPMC8801796 | biostudies-literature
Unknown Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.
| S-EPMC8993158 | biostudies-literature
Unknown Total synthesis of antiviral drug, nirmatrelvir (PF-07321332).
| S-EPMC9579207 | biostudies-literature
Unknown Intranasal or airborne transmission-mediated delivery of an attenuated SARS-CoV-2 protects Syrian hamsters against new variants.
| S-EPMC10250859 | biostudies-literature